A brand-new look!

We are excited to announce that Julius Clinical has a brand-new look and website as part of the ongoing evolution of our company’s brand.
Why?
Ever since its foundation in 2008, Julius Clinical has been based on a unique triangle of scientific rigor, operational excellence, and strong site networks. While this remains the core of our company, we have grown and evolved over the past 15 years, and we came to realize that we have become so much more. This is symbolized by the hexagon in our new logo, that surrounds the well-known triangle.
When. Trials. Matter.
Over the past months, we analysed our organization’s values and created a brand identity that reflects those values. Our pay-off: “When.Trials.Matter.” reflects our endless commitment to supporting global clinical drug trials that will have a major impact on medicine and make a real difference to lives all around the world.
A big thank you
The rebranding has been a major process, involving many people from both inside and outside the organisation. We would like to express our appreciation to everyone who has contributed to this process. We could not have done it without you!
What’s next?
Over the coming weeks, the changes will become more and more visible. But for now, we would like to invite you to explore our brand-new website.
Related news
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners
Julius Clinical Research Receives Growth Investment from Ampersand Capital Partners Partnership will further expand Julius’ clinical trial services capabilities to advance new therapeutics. Zeist, Netherlands, November 28, 2023 -- Julius Cli...
64% of all surveyed physicians underestimated the prevalence of NAFLD (now designated as MASLD)
We are proud to announce the publication of our latest research article titled "A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey." This article summarizes the findings of the AwareNASH ...
Hemodiafiltration in renal failure reduces the risk of death by 23% compared to hemodialysis
Last Friday, the results of the CONVINCE trial were published in the prestigious New England Journal of Medicine. We are thrilled to announce that the CONVINCE study has shown that the use of high-dose hemodiafiltration led to a remarkable 23% low...